Moderna, Inc. (MRNA) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Earnings Reports
-
Moderna (MRNA) Q2 2026: R&D Costs Drop 7% as Pipeline Readouts Approach
July 31, 2026
-
Moderna (MRNA) Q4 2025: Cost Cuts Slash OpEx 30%, Setting Stage for 10% Growth Pivot
June 15, 2026
-
Moderna (MRNA) Q1 2026: International Sales Drive 80% Mix, Litigation Charge Clouds Profit Path
May 01, 2026
-
Moderna (MRNA) Q2 2025: Operating Expenses Cut by $400M as Pipeline Progress Offsets Revenue Shift
August 01, 2025
-
Moderna (MRNA) Q1 2025: R&D Spend to Drop 55% by 2027 as Pipeline Focus Tightens
July 07, 2025